Previous 10 | Next 10 |
2023-03-29 16:28:37 ET Bolt Therapeutics ( NASDAQ: BOLT ) is up 7% in after-hours trading after reporting positive top-line results on BDC-1001 both alone and in combination with Opdivo (nivolumab) for multiple tumor types. The Immune-Stimulating Antibody Conjugate is ...
Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safety BDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in combination ...
BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumab Data support selection of a recommended Phase 2 dose and advancement into Phase 2 studies in breast, ...
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2023) - Bolt Metals Corp. (CSE: BOLT) (FSE: A2QEUB) (OTCQB: PCRCF) (" Bolt " or the " Company ") announces it has implemented a consolidation (the " Consolidation ") of its issued share capital on the basis of one (1) new common share for ev...
Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2023) - Bolt Metals Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares. As a result, the outstanding shares ...
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rd Annu...
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Bolt Metals Corp. (CSE: BOLT) (FSE: A2QEUB) (OTCQB: PCRCF) (" Bolt " or the " Company ") announces it intends to consolidate the Company's issued share capital on a ratio of one (1) new post-consolidated common share for every te...
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in Februa...
Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q3 GAAP EPS of -$0.58 misses by $0.01 . Revenue of $2.1M (+162.5% Y/Y) beats by $0.87M . For further details see: Bolt Biotherapeutics GAAP EPS of -$0.58 misses by $0.01, revenue of $2.1M beats by $0.87...
– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 – BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022 – Cash balance of $209.6 million anticipated to fund key milestones through 2025 ...
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
Bolt Biotherapeutics Inc. Website:
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased securities of Bolt Biotherapeut...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 147.2% to $0.705 on volume of 1,314,512,517 shares SiNtx Technologies Inc. (SINT) rose 132.0% to $0.1276 on volume of 976,185,336 shares Greenwave Technology Solutions Inc. (GWAV) r...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...